Synthetic peptide, and cosmetic composition or pharmaceutical composition and application thereof
US-2024352069-A1 · Oct 24, 2024 · US
US9695217B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9695217-B2 |
| Application number | US-201514968386-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 14, 2015 |
| Priority date | Jan 29, 2010 |
| Publication date | Jul 4, 2017 |
| Grant date | Jul 4, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are small peptide domains and consensus sequences that bind small target molecules of industrial importance, e.g., metals such as nickel, β carotene, and isoflavones such as genistein. Also described are fusion proteins containing such binding domains fused to proteins or to peptide domains like GST or CBD that bind other ligands and can be used to immobilize the target binding domain on a support. One class of fusion proteins that is useful in industrial settings are fusions that contain concatemers of target binding domains, which increases the binding equivalents per molecule.
Opening claim text (preview).
What is claimed is: 1. An isolated non-naturally occurring fusion polypeptide or isolated non-naturally occurring fusion peptide comprising a carotenoid binding peptide comprising a sequence of the formula X 1 X 2 GWX 3 HyX 4 X 5 X 6 (SEQ ID NO:120) Wherein Hy is an aromatic amino acid; X 1 is alanine, valine, leucine, glutamine, tryptophan, tyrosine, serine, proline, threonine or isoleucine; X 2 is alanine, glycine, isoleucine or valine; X 3 is tryptophan, methionine, glycine, proline, leucine, or serine; X 4 is tryptophan, phenylalanine, methionine, glycine, threonine, or histidine; X 5 is glycine, tryptophan, serine, phenylalanine, leucine, glutamine, or alanine; and X 6 is threonine, glycine, tryptophan, alanine, methionine, asparagine, or valine. 2. The isolated polypeptide or peptide of claim 1 wherein X 2 is alanine. 3. The isolated polypeptide or peptide of claim 1 wherein Hy is tryptophan. 4. The isolated polypeptide or peptide of claim 1 wherein X 4 is a tryptophan. 5. An isolated non-naturally occurring fusion polypeptide or isolated non-naturally occurring fusion peptide comprising a carotenoid binding peptide comprising a sequence X 1 WX 2 Hy (SEQ ID NO:121) where Hy is an aromatic amino acid; X 2 is any amino acid; and X 1 is a single amino acid selected from glycine, proline or leucine. 6. The isolated polypeptide or peptide of claim 5 wherein X 1 is glycine.
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
Tripeptides · CPC title
having 5 to 11 amino acids · CPC title
involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)} · CPC title
Fusion polypeptide · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.